GLPG Stock Overview
A biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Galapagos NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €27.31 |
| 52 Week High | €42.46 |
| 52 Week Low | €24.16 |
| Beta | 0.060 |
| 11 Month Change | -5.66% |
| 3 Month Change | -7.86% |
| 1 Year Change | -27.21% |
| 33 Year Change | -43.39% |
| 5 Year Change | -86.02% |
| Change since IPO | 247.90% |
Recent News & Updates
Recent updates
Galapagos: CAR-T Biotech To Change Landscape With GLPG5101 And Beyond
Aug 23Galapagos: Pipeline Still Progressing Despite Financial Volatility
Mar 07Galapagos: Trading At Discount To Cash With A Fast-Growing Marketed Product
Oct 10EMA panel approves amending label for Galapagos' Jyseleca on testicular function effects
Oct 03Galapagos stock dips after Jefferies slashes rating citing challenges ahead
Jul 25Galapagos: Can The Company Turn Around?
May 19Galapagos: A History Of Disruptive Failures
Feb 22Galapagos: The Investment Thesis Is More Appealing Than Ever
Dec 02Galapagos, Gilead's Selection study on filgotinib in ulcerative colitis published in the Lancet
Jun 04Galapagos reports Q1 results
May 06Galapagos: Market Values Pipeline Below $0
Dec 30Galapagos candidate shows positive action in IPF proof-of-concept study
Nov 30Galapagos NV 2020 Q3 - Results - Earnings Call Presentation
Nov 06Galapagos Is A Buy Despite Setback In The U.S.
Oct 23Shareholder Returns
| GLPG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.1% | 2.5% | 2.2% |
| 1Y | -27.2% | 16.1% | 31.6% |
Return vs Industry: GLPG underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: GLPG underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| GLPG volatility | |
|---|---|
| GLPG Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GLPG has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GLPG's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 683 | Paul Stoffels | www.glpg.com |
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l.
Galapagos NV Fundamentals Summary
| GLPG fundamental statistics | |
|---|---|
| Market cap | US$1.80b |
| Earnings (TTM) | -US$63.61m |
| Revenue (TTM) | US$272.98m |
6.6x
P/S Ratio-28.3x
P/E RatioIs GLPG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLPG income statement (TTM) | |
|---|---|
| Revenue | €260.09m |
| Cost of Revenue | €331.48m |
| Gross Profit | -€71.38m |
| Other Expenses | -€10.77m |
| Earnings | -€60.61m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 12, 2025
| Earnings per share (EPS) | -0.92 |
| Gross Margin | -27.45% |
| Net Profit Margin | -23.30% |
| Debt/Equity Ratio | 0% |
How did GLPG perform over the long term?
See historical performance and comparison